长期使用阿片类药物患者中阿片诱导性肾上腺功能不全的患病率
该横断面研究纳入102例因慢性疼痛在疼痛康复中心使用阿片类药物的成人患者,采用病例检测(皮质醇<10 mcg/dL、ACTH<15 pg/mL、DHEAS<25 mcg/dL)并经内分泌评估确认,诊断阿片诱导性肾上腺功能不全(OIAI)9例(9%)。OIAI患者累积阿片暴露量更高,且日吗啡毫克当量(MME)≥20 mg者应监测OIAI。
要点
- 慢性阿片使用者中OIAI患病率为9%,异常病例检测率为10.8%。
- 累积阿片暴露量是OIAI的唯一预测因素,OIAI组中位累积暴露为13,440 mg*months。
- 日MME≥20 mg者应监测OIAI;停药后7例中6例肾上腺功能恢复。
核心结论
- 在慢性疼痛长期使用阿片类药物的成人中,OIAI患病率为9%,累积阿片暴露量是OIAI发生的唯一预测因素。
研究设计与样本
- 2016-2018年单中心横断面研究,纳入疼痛康复中心102例使用慢性阿片类药物的成人患者。
- 中位年龄53岁(范围22-83),67%为女性;中位日MME为60 mg(3-840),中位阿片治疗时长60个月(3-360)。
主要发现
- 11例(10.8%)病例检测异常,9例(9%)确诊OIAI。
- OIAI组中位日MME为140 mg(20-392),非OIAI组为57 mg(3-840),P=0.1。
- OIAI组累积阿片暴露量中位13,440 mg*months,非OIAI组3120 mg*months,P=0.03。
- 日MME<20 mg者无OIAI发生(MME>20 mg的敏感性100%),但MME>20 mg截断值的特异性仅19%。
- 停用阿片后7例中6例肾上腺功能恢复。
关键数值与推荐
- OIAI病例检测标准:皮质醇<10 mcg/dL、ACTH<15 pg/mL、硫酸脱氢表雄酮<25 mcg/dL,并经内分泌评估确认。
- 日MME≥20 mg者应监测OIAI。
临床怎么用
- 对长期使用阿片类药物的慢性疼痛患者,尤其日MME≥20 mg或累积暴露量高者,应考虑筛查OIAI。
- 疑似OIAI应结合皮质醇、ACTH及DHEAS进行病例检测,并转内分泌评估确认。
- 确诊OIAI者可考虑停用阿片,研究显示多数患者肾上腺功能可恢复。
局限性
- 单中心横断面设计,样本量102例,OIAI组仅9例。
- MME>20 mg截断值敏感性100%但特异性仅19%,筛查效能有限。
- 原文未报告多变量校正分析及长期随访数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Chronic opioid use may lead to adrenal insufficiency because of central suppression of the hypothalamic-pituitary-adrenal axis. However, the prevalence of opioid-induced adrenal insufficiency (OIAI) is unclear. OBJECTIVE: To determine the prevalence of OIAI and to identify predictors for the development of OIAI in patients taking opioids for chronic pain. DESIGN: Cross-sectional study, 2016-2018. SETTING: Referral center. PATIENTS: Adult patients taking chronic opioids admitted to the Pain Rehabilitation Center. MAIN OUTCOME MEASURE: Diagnosis of OIAI was considered if positive case detection (cortisol < 10 mcg/dL, ACTH < 15 pg/mL, and dehydroepiandrosterone sulfate < 25 mcg/dL), and confirmed after endocrine evaluation. Daily morphine milligram equivalent (MME) was calculated. RESULTS: In 102 patients (median age, 53 years [range, 22-83], 67% women), median daily MME was 60 mg (3-840), and median opioid therapy duration was 60 months (3-360). Abnormal case detection testing was found in 11 (10.8%) patients, and diagnosis of OIAI was made in 9 (9%). Patients with OIAI were on a higher daily MME (median, 140 [20-392] mg vs 57 [3-840] mg, P = 0.1), and demonstrated a 4 times higher cumulative opioid exposure (median of 13,440 vs 3120 mg*months, P = 0.03). No patient taking <MME of 20 mg/day developed OIAI (sensitivity of 100% for MME > 20 mg); however, specificity of MME cutoff >20 mg was only 19%. After opioid discontinuation, 6/7 patients recovered adrenal function. CONCLUSION: The prevalence of OIAI was 9%, with MME cumulative exposure being the only predictor for OIAI development. Patients on MME of 20 mg/day and above should be monitored for OIAI.
引用
- Li T, Cunningham JL, Gilliam WP, et al. Prevalence of Opioid-Induced Adrenal Insufficiency in Patients Taking Chronic Opioids. J Clin Endocrinol Metab. 2020. PMID: 32866966. doi:10.1210/clinem/dgaa499
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。